CHIMRAR has registered the first import test for coronavirus
Mass media

CHIMRAR has registered the first import test for coronavirus

04/27/2020

The diagnostic system is based on the real-time reverse transcription polymerase chain reaction (RT-PCR) method. The test kit targets three sites of the coronavirus RNA-the E gene, the RdRp gene and the N gene. The duration time is 120 minutes, diagnostic sensitivity is 95%, specificity is 100%.

Osang Healthcare received European certification for the product in February 2020. In March 2020, the Korean authorities approved the export of tests, and in mid-April 2020, the test system received authorization from the US FDA. The US has already purchased a batch of tests for a total of $3 million.

Osang Healthcare was founded in 1996 and specializes in the development of diagnostic devices: it produces test systems for immune and molecular diagnostics, devices for measuring blood sugar, hemoglobin and cholesterol levels.



According to SPARK-Interfax, Avivir LLC was registered in 2019 and is 100% owned by Himrar-Pharma LLC. The company's financial indicators are not disclosed. On its website, the supplier offers tests for antibodies to SARS-Cov-2 produced by the Chinese Innovita Biological Technology Co.

Earlier, Himrar announced a project to produce a domestic generic Favipiravir for the treatment of patients with coronavirus. The company will create a joint venture with the RDIF, which will promote the drug. The first batches can be delivered in April, in 2020 it is planned to produce 600 thousand packages of the drug.

Currently, 15 tests for SARS-Cov-2 have been registered in Russia: from state manufacturers, the holders of RU are subordinate institutions of Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor), FMBA, the Ministry of Defense, from private companies – LLC "NPF "Litech", JSC "Vector-Best", LLC "DNA Technologies TS", the pharmaceutical company "Generium", a joint venture of LLC "Genetic Technologies" and the Japanese K. K. Mirai Genomics LLC "Evotek-Mirai Genomics" and other companies.

The article is published on Vademecum


News and articles

  • The most effective rapid coronavirus tests

    Snob magazine has published an article about the most effective tests for coronavirus infection detection, among which there are "Avivir" company tests.

    СМИ
  • Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor) has equated antigen tests for COVID-19 to PCR

    The decree of the chief state sanitary doctor of the Russian Federation Anna Popova now provides for the use of the methods that determine the genetic material or antigen of the pathogen, and not only the PCR method, when testing for the detection of SARS-CoV-2. Shortly before the appearance of this document, scientists from The Gamaleya National Center of Epidemiology and Microbiology Research Center presented research results demonstrating that in some cases the value of antigenic tests may be higher than PCR. Learn more: https://vademec.ru/news/2021/03/31/rospotrebnadzor-priravnyal-antigennye-testy-na-covid-19-k-ptsr/

    СМИ
  • What rapid tests are able to assess immunity to COVID-19

    The Russian company Avivir was the first to introduce two RBD tests to the domestic market for rapid diagnosis of the immune response to new coronavirus infection. The test systems presented by Avivir are designed for the qualitative detection of IgG class antibodies to the receptor-binding domain (RBD) of the SARS-CoV-2 S-protein. These screening tools from the South Korean manufacturer Sugentech and the Russian Rapid Bio determine the presence of virus-neutralizing anti-RBD antibodies in the blood.

    СМИ

Get a consultation

Leave a request and we will advise you on the purchase of products